C4 Therapeutics FY EPS $(2.67) Down From $(2.62) YoY, Sales $20.76M Down From $31.10M YoY
Portfolio Pulse from Benzinga Newsdesk
C4 Therapeutics (NASDAQ:CCCC) reported a decrease in FY EPS to $(2.67) from $(2.62) YoY and a 33.25% drop in sales to $20.76M from $31.10M YoY.
February 22, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
C4 Therapeutics reported a decrease in FY EPS to $(2.67) from $(2.62) YoY and a significant drop in sales, indicating potential challenges ahead.
The reported decrease in both earnings per share and sales for C4 Therapeutics suggests potential financial challenges for the company. This could lead to negative investor sentiment in the short term, likely impacting the stock price negatively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100